Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;93(3):1573-1580.
doi: 10.1002/jmv.26492. Epub 2020 Oct 8.

Analysis of the prophylactic effect of thymosin drugs on COVID-19 for 435 medical staff: A hospital-based retrospective study

Xiulan Liu  1 , Yi Liu  1 , Liuming Wang  2 , Luhong Hu  3 , Dong Liu  1 , Juan Li  1
Affiliations

Analysis of the prophylactic effect of thymosin drugs on COVID-19 for 435 medical staff: A hospital-based retrospective study

Xiulan Liu et al. J Med Virol. 2021 Mar.

Abstract

To explore the role of thymosin drugs in the prevention of novel coronavirus disease (COVID-19), we analyzed the preventive effects of different medication timings on health medical staff, and then provided recommendations for pharmaceutical monitoring of thymus drugs. The hospital-based retrospective study analyzed 435 medical staffers, treated with or without thymosin drugs as preventive medicines in our hospital of Wuhan City, from January 25 to March 25, 2020. For the prophylactics, the medical staff was prevented from pre-exposure prophylaxis (risk prevention of exposure to COVID-19 patients before using thymosin drugs) and postexposure prophylaxis (risk prevention of exposure to COVID-19 patients after using thymosin drugs). The effectiveness and safety of thymosin drugs were studied in the prevention and control of COVID-19 application, in real-world data research for the application of the drug for COVID- 19. In a similar exposure environment, compared to medical staffers who did not take preventive medicine, the use of thymosin drugs, before exposure and after exposure had an insignificant effect, and the adverse drug reaction (ADR) was increased, especially when thymosin drugs were used together with α-interferon.

Keywords: ADR; COVID-19; SARS-CoV-2; prophylactic; thymosin drugs.

PubMed Disclaimer

References

REFERENCES

    1. World Health OrganizationClinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (‎2019-NCoV)‎ Infection Is Suspected: Interim Guidance, 28 January 2020. World Health Organization; 2020.
    1. Han Q, Lin Q, Jin S, You L Recent insights into 2019-nCoV: a brief but comprehensive review. J Infect 2020.
    1. Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55:105924.
    1. Li S, Wang R, Zhang Y, et al. Symptom combinations associated with outcome and therapeutic effects in a cohort of cases with SARS. Am J Chin Med. 2006;34(6):937-947.
    1. Lu Y, Gong L, Tong D. Analysis of the therapeutic effect of 3485 cases of thymus pentageptide to prevent SARS. J Chin Clin Med. 2004;5(3):109-110.